A protein in spinal fluid may explain why radiation works less well for some people
Original title: CXCL1-CXCR2 signaling mediates cancer cell growth and response to radiation therapy in leptomeningeal metastasis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
The drug part was tested only in mice.
The short version
Scientists found a protein that seems to help this cancer grow and to blunt radiation.
What was studied. Researchers tested the spinal fluid of people with cancer that spread to the linings of the brain and spine. They checked it before and after radiation to the brain and spine. They also studied mice with the same kind of cancer spread.
What they found. People with more of a protein called CXCL1 before radiation did worse with the radiation. In mice, stopping the cancer cells from making this protein slowed the cancer's growth in those linings. A drug that blocks the protein's partner, called CXCR2, also slowed growth and made radiation work better in mice. In people, higher levels of CXCR2 before radiation went along with a shorter time of living.
What this means, and what it doesn't
What it could mean: This may help explain why the same radiation helps some people more than others. It also points to a possible way to make that radiation work better. A test of this protein could one day help doctors know what to expect.
What it doesn't mean: This is not a treatment anyone can get today. The drug was tested only in mice and in lab models, not in people. No one has shown it is safe or helpful for a person. It is not a cure, and it is far from everyday care.
Source: PubMed, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.